The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events | Annals of the Rheumatic Diseases

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Archive
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Article info

Clinical and epidemiological research

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

Authors

J P Leombruno PubMed articles Google scholar articles
T R Einarson PubMed articles Google scholar articles
E C Keystone PubMed articles Google scholar articles

Dr J P Leombruno, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Suite 604, Toronto, Ontario, Canada M5S 3M2; john.leombruno{at}utoronto.ca

Citation

Leombruno JP, Einarson TR, Keystone EC

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

Annals of the Rheumatic Diseases 2009;68:1136-1145.

Publication history

Accepted August 3, 2008
First published August 27, 2008.

Online issue publication

March 09, 2023

Article Versions

Previous version (25 October 2017).
You are viewing the most recent version of this article.

Copyright information

2009 BMJ Publishing Group and European League Against Rheumatism